These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
52. Vaginal delivery of contraceptives. Sitruk-Ware R Expert Opin Drug Deliv; 2005 Jul; 2(4):729-36. PubMed ID: 16296797 [TBL] [Abstract][Full Text] [Related]
53. Melanoma in female patients: general features and focus on the impact of estro-progestinic pills in prognostic factors. Paolino G; Moliterni E; Didona D; Corsetti P; Lopez T; Abbenante D; Calvieri S; Bottoni U G Ital Dermatol Venereol; 2018 Aug; 153(4):582-585. PubMed ID: 29767487 [No Abstract] [Full Text] [Related]
57. Intravaginal oestrogen and progestin administration: advantages and disadvantages. Cicinelli E Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):391-405. PubMed ID: 17981510 [TBL] [Abstract][Full Text] [Related]
58. Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study. Fleischer K; van Vliet HA; Rosendaal FR; Rosing J; Tchaikovski S; Helmerhorst FM Thromb Res; 2009; 123(3):429-35. PubMed ID: 18829069 [TBL] [Abstract][Full Text] [Related]
59. Oral contraceptive agents and the glucose tolerance problem. Cohn RE Pa Med; 1971 Jan; 74(1):62-4. PubMed ID: 5540284 [No Abstract] [Full Text] [Related]
60. Contraception for women: an evidence based overview. Amy JJ; Tripathi V BMJ; 2009 Aug; 339():b2895. PubMed ID: 19666684 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]